Professor
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China., Tianjin, China (People's Republic)
Mu Hao, M.D./Ph.D.
Prof. Hao received her PhD degree in 2007 at Sichuan University of China then completed the postdoc training in University of Iowa, USA. Now she is the Professor and Principal Investigator of Department of State Kay Lab of Experimental Hematology, Institution of Hematology and Blood Disease Hospital, Chinese Academy of Medical Science. She is an investigator who has focused on myeloma and the related diseases for more than 10 years basically and translationally and has published many peer-reviewed scientific papers in this field. The main emphasis of her research is to identify the pathogenesis of multiple myeloma and other malignancy of plasma cells. Multiple Myeloma is a heterogeneous disease with a complex genetic landscape, characterized by several numerical and structure aberrations. Despite proteasome inhibitors (PIs) have transformed management of multiple myeloma (MM) and improved the outcome of patients, MM still incurable. Drug resistance remains the key problem and causes refractory and relapsed in MM. Her current interest is focus on the functional investigation of oncogenes and biological heterogeneity of tumor cells involved in myeloma development and drug resistance. Another one is focus on the tumor microenvironment interaction with tumor cells in the pathogenesis and progression of multiple myeloma.
Dr. Hao is active in academic activities and is also the committee members of national academic societies, and peer reviewer for several domestic and international journals.
Wednesday, September 27, 2023
6:33 PM – 6:45 PM EEST